INTRODUCTION: Maternal obesity (MO) remains a serious obstetric problem with acute and chronic morbidities for both mothers and offspring. The mechanisms underlying these adverse consequences of MO remain unknown. Endocannabinoids (ECB) are neuromodulatory lipids released from adipocytes and other tissues. Metabolic crosstalk between placenta and adipocytes may mediate sequelae of MO. The goal of this study was to elucidate placental and systemic ECB in MO. MATERIAL AND METHODS: Placentas, sera, and subcutaneous fat were collected at Cesarean sections performed near term (0.9 G) in four non-obese (nOB) and four obese (OB) baboons (Papio spp.). Concentrations of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured by liquid chromatography coupled to tandem mass spectrometry. AEA and 2-AG pathways were characterized in placentas by Q-RT-PCR, Western blot and immunohistochemistry. RESULTS: Placental 2-AG levels were lower and maternal fat AEA levels were higher in OB (1254.1 ± 401.3 nmol/kg and 17.3 ± 4 nmol/kg) vs. nOB (3124.2 ± 557.3 nmol/kg and 3.1 ± 0.6 nmol/kg) animals. Concentrations of 2-AG correlated positively between maternal fat and placenta (r = 0.82, p = 0.013), but correlated negatively with maternal leptin concentrations (r = -0.72, p = 0.04 and r = -0.83, p = 0.01, respectively). CONCLUSION: This is the first study to demonstrate differential ECB pathway regulation in maternal fat and placenta in MO. Differential regulation and function exist for AEA and 2-AG as the major ECB pathways in placenta.
INTRODUCTION:Maternal obesity (MO) remains a serious obstetric problem with acute and chronic morbidities for both mothers and offspring. The mechanisms underlying these adverse consequences of MO remain unknown. Endocannabinoids (ECB) are neuromodulatory lipids released from adipocytes and other tissues. Metabolic crosstalk between placenta and adipocytes may mediate sequelae of MO. The goal of this study was to elucidate placental and systemic ECB in MO. MATERIAL AND METHODS: Placentas, sera, and subcutaneous fat were collected at Cesarean sections performed near term (0.9 G) in four non-obese (nOB) and four obese (OB) baboons (Papio spp.). Concentrations of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured by liquid chromatography coupled to tandem mass spectrometry. AEA and 2-AG pathways were characterized in placentas by Q-RT-PCR, Western blot and immunohistochemistry. RESULTS: Placental 2-AG levels were lower and maternal fat AEA levels were higher in OB (1254.1 ± 401.3 nmol/kg and 17.3 ± 4 nmol/kg) vs. nOB (3124.2 ± 557.3 nmol/kg and 3.1 ± 0.6 nmol/kg) animals. Concentrations of 2-AG correlated positively between maternal fat and placenta (r = 0.82, p = 0.013), but correlated negatively with maternal leptin concentrations (r = -0.72, p = 0.04 and r = -0.83, p = 0.01, respectively). CONCLUSION: This is the first study to demonstrate differential ECB pathway regulation in maternal fat and placenta in MO. Differential regulation and function exist for AEA and 2-AG as the major ECB pathways in placenta.
Authors: B M Fonseca; G Correia-da-Silva; A H Taylor; P M W Lam; T H Marczylo; S C Bell; J C Konje; N A Teixeira Journal: Int J Biochem Cell Biol Date: 2010-08-19 Impact factor: 5.085
Authors: Bruno M Fonseca; Georgina Correia-da-Silva; Anthony H Taylor; Patricia M W Lam; Timothy H Marczylo; Justin C Konje; Natércia A Teixeira Journal: Reprod Toxicol Date: 2012-05-18 Impact factor: 3.143
Authors: D Farley; M E Tejero; A G Comuzzie; P B Higgins; L Cox; S L Werner; S L Jenkins; C Li; J Choi; E J Dick; G B Hubbard; P Frost; D J Dudley; B Ballesteros; G Wu; P W Nathanielsz; N E Schlabritz-Loutsevitch Journal: Placenta Date: 2009-07-25 Impact factor: 3.481
Authors: Natalia E Schlabritz-Loutsevitch; Anthony G Comuzzie; Michael M Mahaney; Gene B Hubbard; Edward J Dick; Mehmet Kocak; Sonali Gupta; Maira Carrillo; Mauro Schenone; Arnold Postlethwaite; Andrzej Slominski Journal: Comp Med Date: 2016-04 Impact factor: 0.982
Authors: Iram P Rodriguez-Sanchez; Josee Guindon; Marco Ruiz; M Elizabeth Tejero; Gene Hubbard; Laura E Martinez-de-Villarreal; Hugo A Barrera-Saldaña; Edward J Dick; Anthony G Comuzzie; Natalia E Schlabritz-Loutsevitch Journal: Neurotoxicol Teratol Date: 2016-06-18 Impact factor: 3.763
Authors: D M Popescu-Spineni; L Guja; C M Cristache; M E Pop-Tudose; A M Munteanu Journal: Acta Endocrinol (Buchar) Date: 2022 Apr-Jun Impact factor: 1.104
Authors: N Schlabritz-Loutsevitch; K Apostolakis-Kyrus; R Krutilina; G Hubbard; M Kocak; Z Janjetovic; S Sathanandam; A T Slominski; G Mari; E Dick Journal: J Med Primatol Date: 2016-09-15 Impact factor: 0.667
Authors: Katarzyna Malenczyk; Erik Keimpema; Fabiana Piscitelli; Daniela Calvigioni; Peyman Björklund; Kenneth Mackie; Vincenzo Di Marzo; Tomas G M Hökfelt; Agnieszka Dobrzyn; Tibor Harkany Journal: Proc Natl Acad Sci U S A Date: 2015-10-22 Impact factor: 11.205
Authors: Jakub Fichna; Jodianne T Wood; Malvina Papanastasiou; Subramanian K Vadivel; Piotr Oprocha; Maciej Sałaga; Marta Sobczak; Anna Mokrowiecka; Adam I Cygankiewicz; Piotr K Zakrzewski; Ewa Małecka-Panas; Wanda M Krajewska; Piotr Kościelniak; Alexandros Makriyannis; Martin A Storr Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: N Schlabritz-Loutsevitch; J Maher; R Sullivan; G Mari; M Schenone; H L Cohen; R A Word; G B Hubbard; E J Dick Journal: Sci Rep Date: 2018-01-19 Impact factor: 4.379
Authors: Heloise Labuschagne; C Burns; Stacy Martinez; Maira Carrillo; Melissa Waggoner; Irene Schwanninger; James Maher; Moss Hampton; Javier Flores-Guardado; Natalia E Schlabritz-Loutsevitch Journal: Case Rep Womens Health Date: 2016-10-20